UB Paderborn / Katalog / Suche / in CDI

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Nature communications, 2019-11, Vol.10 (1), p.5167-19, Article 5167

2019

Volltextzugriff (PDF)

Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy

Molecular therapy, 2017-08, Vol.25 (8), p.1917-1932

2017

Volltextzugriff (PDF)

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue

Journal of translational medicine, 2012-06, Vol.10 (1), p.125-125, Article 125

2012

Volltextzugriff (PDF)

Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells

Molecular cancer therapeutics, 2007-02, Vol.6 (2), p.587-598

2007

Volltextzugriff (PDF)

Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris

PloS one, 2013-04, Vol.8 (4), p.e61088-e61088

2013

Volltextzugriff (PDF)

Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia

Pediatric blood & cancer, 2017-11, Vol.64 (11), p.n/a

2017

Volltextzugriff (PDF)

Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling

Journal of translational medicine, 2015-04, Vol.13 (1), p.110-110, Article 110

2015

Volltextzugriff (PDF)

Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors

Journal of translational medicine, 2013-09, Vol.11 (1), p.213-213, Article 213

2013

Volltextzugriff (PDF)

A multi-site feasibility study for personalized medicine in canines with osteosarcoma

Journal of translational medicine, 2013-07, Vol.11 (1), p.158-158, Article 158

2013

Volltextzugriff (PDF)

Melanoma genotypes and phenotypes get personal

Laboratory investigation, 2013-08, Vol.93 (8), p.858-867

2013

Volltextzugriff (PDF)

Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition

Toxicon (Oxford), 2010-04, Vol.55 (4), p.827-837

2010

Volltextzugriff (PDF)

Using a rhabdomyosarcoma patient‐derived xenograft to examine precision medicine approaches and model acquired resistance

Pediatric blood & cancer, 2014-09, Vol.61 (9), p.1570-1577

2014

Volltextzugriff (PDF)

Sensitivity of breast cancer cell lines to recombinant thiaminase I

Cancer chemotherapy and pharmacology, 2010-05, Vol.66 (1), p.171-179

2010

Volltextzugriff (PDF)

112 Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A69-A70

2020

Volltextzugriff (PDF)

Addressing the design of in vitro models for the investigation of microcystins: The essential role of transporter-mediated uptake

Cell biology international, 2010-09, Vol.34 (9), p.907-909

2010

Volltextzugriff (PDF)

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms

American journal of cancer research, 2015-01, Vol.5 (4), p.1507-1518

2015

Volltextzugriff (PDF)

Targeting the NF-κB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs

Journal of cellular biochemistry, 2006-05, Vol.98 (1), p.221-233

2006

Volltextzugriff (PDF)

Anticancer, antichemotactic and antimicrobial activities of marine sponges collected off the coast of Santa Catarina, southern Brazil

Journal of experimental marine biology and ecology, 2002-12, Vol.281 (1), p.1-12

2002

Volltextzugriff (PDF)

Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1813-1813

2021

Volltextzugriff (PDF)

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12

Molecular Therapy Oncology, 2024-03, Vol.32 (1), p.200758-200758, Article 200758

2024

Volltextzugriff (PDF)

Abstract 821: B7-H3 is a potential antibody drug conjugate target for the treatment of prostate cancer

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.821-821

2018

Volltextzugriff (PDF)

Abstract 5544: Newcastle Disease Virus in human derived tumors: Understanding immune recruitment and activation via virally delivered IL-12

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.5544-5544

2020

Volltextzugriff (PDF)

Abstract 76: Synthetic lethal targeting of BRCA mutant tumors with antibody linked pyrrolobenzodiazepine dimers

Cancer research (Chicago, Ill.), 2017-07, Vol.77 (13_Supplement), p.76-76

2017

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors

Oncolytic VSV Primes Differential Responses to Immuno-oncology Therapy

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue

Potent cytotoxicity of the phosphatase inhibitor microcystin LR and microcystin analogues in OATP1B1- and OATP1B3-expressing HeLa cells

Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer

Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris

Characterization of the anti‐CD22 targeted therapy, moxetumomab pasudotox, for B‐cell precursor acute lymphoblastic leukemia

Anoikis-resistant subpopulations of human osteosarcoma display significant chemoresistance and are sensitive to targeted epigenetic therapies predicted by expression profiling

Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors

A multi-site feasibility study for personalized medicine in canines with osteosarcoma

Melanoma genotypes and phenotypes get personal

Abrogation of microcystin cytotoxicity by MAP kinase inhibitors and N-acetyl cysteine is confounded by OATPIB1 uptake activity inhibition

Using a rhabdomyosarcoma patient‐derived xenograft to examine precision medicine approaches and model acquired resistance

Sensitivity of breast cancer cell lines to recombinant thiaminase I

112 Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy

Addressing the design of in vitro models for the investigation of microcystins: The essential role of transporter-mediated uptake

Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms

Targeting the NF-κB pathway in estrogen receptor negative MDA-MB-231 breast cancer cells using small inhibitory RNAs

Anticancer, antichemotactic and antimicrobial activities of marine sponges collected off the coast of Santa Catarina, southern Brazil

Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305

Abstract 1813: The genetic makeup of patient-derived xenografts shapes the immune landscape of humanized mice tumors

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12

Abstract 821: B7-H3 is a potential antibody drug conjugate target for the treatment of prostate cancer

Abstract 5544: Newcastle Disease Virus in human derived tumors: Understanding immune recruitment and activation via virally delivered IL-12

Abstract 76: Synthetic lethal targeting of BRCA mutant tumors with antibody linked pyrrolobenzodiazepine dimers

Suchergebnisse filtern